The Infectious Diseases Society of America has recommended that the criteria for systemic inflammation in COVID-19 patients be a CRP value of ≥75 mg/L, and that such patients be given both dexamethasone and monoclonal antibody therapy [32]. This evidence concerns the gene CRP and COVID-19.